 |
인쇄하기
취소
|
Health authorities have no intention to re-evaluate efficacy of Ursa
The Ministry of Food and Drug Safety (MFDS) said it has not any plan to re-evaluate the efficacy of Ursa produced by Daewoong Pharm amid escalating dispute over the therapeutic effect of the liver function enhancer.
In a phone-call with Yakup Shinmoon, a local trade paper, the MFDS official Lee Dong-hee said Tuesday that the ministry has no plan to re-assess the efficacy of Ursa as the drug ...
In a phone-call with Yakup Shinmoon, a local trade paper, the MFDS official Lee Dong-hee said Tuesday that the ministry has no plan to re-assess the efficacy of Ursa as the drug ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.